Please be advised that Diagnostic Solutions Laboratory has implemented a slight price increase on select tests. These updated prices are now reflected in our test menu. We encourage you to review the revised pricing prior to placing any new orders. As always, we sincerely appreciate your continued partnership and business.
“JuneMensHealth2022”/

DID YOU KNOW?

On average, men die five years younger than women and die at higher rates from nine of the top 10 causes of death. 1 in 2 men are diagnosed with cancer in their lifetime, compared to 1 in 3 women. 70% of developmental and learning disabilities affect males.

The goal of Evexia’s Men’s Health Awareness month is to heighten the awareness of preventable health problems and encourage the early detection and treatment of disease among males of all ages. June is an excellent time to encourage men and boys to seek regular medical advice and to take care of their health now and in the future.

DID YOU KNOW?

Erectile dysfunction (ED) is the recurrent and persistent inability to achieve and/or maintain an erection adequate to permit sexual performance for at least three months. ED affects more than 50% of men between the ages of 40 and 70 years and rates rise over 70% for patients above 70. Conditions to screen for include Peyronie’s disease, cardiovascular disease, neurological conditions, and mental health conditions.*

Lab Test Consideration:

  • Evexia Complete Male Hormone Profile
  • Evexia Comprehensive Diabesity Panel
  • Evexia Comprehensive Diabetes Panel
  • Prostate-Specific Antigen (PSA)
  • Prostate-Specific Antigen (PSA), Free PSA: Total PSA Ratio
  • Evexia Complete Cardiovascular Panel

Testosterone deficiency syndrome (TDS) can affect men of all ages, have a variety of underlying causes, and present with a myriad of symptoms. While there are long term risks associated with untreated TDS, the short terms risks are likely minimal. However, men must be careful triaged to assess for underlying dangerous medical conditions. Conditions to screen for include prostate cancer, benign prostatic hyperplasia, testicular abnormalities, and pituitary disorders.*

Lab Test Consideration:

  • Evexia Complete Male Hormone Profile

    • Benign prostatic hyperplasia (BPH) and male lower urinary tract symptoms (LUTS) generally have protracted courses, with slow worsening of symptoms over time. Based on prospective studies, the chance of a male with moderate to severe LUTS going into acute urinary retention (AUR) is approximately 0.6–1.8% per year, with a similar risk of developing infections, bladder stones, or upper tract deterioration. Given the low risk of adverse events and the current pandemic, it is reasonable to monitor symptom progression. However, it’s important to investigate and rule out more serious pathological conditions such as prostate and bladder cancer. *

    Lab Test Consideration:

    • Prostate-Specific Antigen (PSA)
    • Prostate-Specific Antigen (PSA), Free PSA: Total PSA Ratio
    • Evexia Complete Male Hormone Profile

    Evexia Diagnostics is proud to promote men's health awareness by offering specific laboratory tests and Evexia nutraceuticals to bolster the health of your clients and patients:

    Evexia Panels

  • Evexia Complete Male Hormone Profile

  • Evexia Comprehensive Wellness Panel

  • Evexia Premier Wellness Panel

  • Evexia Basic Cardiovascular Panel

  • Evexia Complete Cardiovascular Panel

  • Evexia Comprehensive Cardiovascular Panel

  • Evexia Premier Cardiovascular Panel

    •    
    Click here to search for the above panels and test kits in the Evexia TEST MENU SEARCH.

    Evexia Nutraceutical Recommendations:

    Click here to search for the above Evexia Nutraceuticals™ in the Evexia Store.
    References
    *
    Bella AJ, Lee JC, Grober ED, et al. 2018 Canadian Urological Association guideline for Peyronie’s disease and congenital penile curvature. Can Urol Assoc J. 2018;12:E197–209. doi: 10.5489/cuaj.5255.
    Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol. 1994;151:54–61.
    Witherspoon L, Fitzpatrick R, Patel P, et al. Clinical pearls to managing men's health conditions during the COVID-19 pandemic. Can Urol Assoc J. 2020;14(5):E161-E166. doi:10.5489/cuaj.6631
    **
    Witherspoon L, Fitzpatrick R, Patel P, et al. Clinical pearls to managing men's health conditions during the COVID-19 pandemic. Can Urol Assoc J. 2020;14(5):E161-E166.
    ***
    McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387–98.
    Roehrborn CG, Bruskewitz R, Nickel GC, et al. Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS study group. Eur Urol. 2000;37:528–36.
    Witherspoon L, Fitzpatrick R, Patel P, et al. Clinical pearls to managing men's health conditions during the COVID-19 pandemic. Can Urol Assoc J. 2020;14(5):E161-E166.